Interferon α/β receptor knockout mice as a model to study bluetongue virus infection

Virus Research

Volumn 182, Issue , 2014, Pages 35-42

  Ortego, Javier ^a   De la Poza, Francisco ^a   Marín López, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

Bluetongue virus; IFNAR( ) mice; Orbiviruses

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; BLUETONGUE VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARTICLE; ARTIODACTYLA; BLUETONGUE; BLUETONGUE ORBIVIRUS; BLUETONGUE VIRUS 1; BLUETONGUE VIRUS 4; BLUETONGUE VIRUS 8; CATTLE; DEER; DISEASE COURSE; DRUG EFFICACY; GOAT; IMMUNE RESPONSE; INFECTION SENSITIVITY; KNOCKOUT MOUSE; LETHALITY; LIVESTOCK; NONHUMAN; PRIORITY JOURNAL; SHEEP; VACCINATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALIA; ARTHROPODA; BLUETONGUE VIRUS; BOS; CAMELIDAE; CAPRA HIRCUS; CERVIDAE; MUS; ORBIVIRUS; OVIS ARIES;

BLUETONGUE VIRUS; IFNAR(-/-) MICE; ORBIVIRUSES;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; VIRAL VACCINES;

EID: 84896318563     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.09.038     Document Type: Article

References (72)

1. Alexander K.A., MacLachlan N.J., Kat P.W., House C., O'Brien S.J., Lerche N.W., Sawyer M., Frank L.G., Holekamp K., Smale L., et al. Evidence of natural bluetongue virus infection among African carnivores. Am. J. Trop. Med. Hyg. 1994, 51(5):568-576.
2. Aly H.H., Oshiumi H., Shime H., Matsumoto M., Wakita T., Shimotohno K., Seya T. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS ONE 2011, 6(6):e21284.
3. Anderson J., Hagglund S., Breard E., Comtet L., Lovgren Bengtsson K., Pringle J., Zientara S., Valarcher J.F. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue Virus serotype 8 in ca ttle. Clin. Vaccine Immunol. 2013, 20(8):1115-1122.
4. Barratt-Boyes S.M., MacLachlan N.J. Dynamics of viral spread in bluetongue virus infected calves. Vet. Microbiol. 1994, 40(3-4):361-371.
5. Bereczky S., Lindegren G., Karlberg H., Akerstrom S., Klingstrom J., Mirazimi A. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J. Gen. Virol. 2010, 91(Pt 6):1473-1477.
6. Boshra H., Lorenzo G., Rodriguez F., Brun A. A DNA vaccine encoding ubiquitinated Rift valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 2011, 29(27):4469-4475.
7. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., Haller O. Genetic evidence for an interferon-antagonistic function of Rift valley fever virus nonstructural protein NSs. J. Virol. 2001, 75(3):1371-1377.
8. Bowen R.A., Howard T.H., Pickett B.W. Interaction of bluetongue virus with preimplantation embryos from mice and cattle. Am. J. Vet. Res. 1982, 43(11):1907-1911.
9. Calvo-Pinilla E., Navasa N., Anguita J., Ortego J. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS ONE 2012, 7(4):e34735.
10. Calvo-Pinilla E., Nieto J.M., Ortego J. Experimental oral infection of bluetongue virus serotype 8 in type I interferon receptor-deficient mice. J. Gen. Virol. 2010, 91(Pt 11):2821-2825.
11. Calvo-Pinilla E., Rodriguez-Calvo T., Anguita J., Sevilla N., Ortego J. Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS ONE 2009, 4(4):e5171.
12. Calvo-Pinilla E., Rodriguez-Calvo T., Sevilla N., Ortego J. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 2009, 28(2):437-445.
13. Caporale M., Wash R., Pini A., Savini G., Franchi P., Golder M., Patterson-Kane J., Mertens P., Di Gialleonardo L., Armillotta G., Lelli R., Kellam P., Palmarini M. Determinants of bluetongue virus virulence in murine models of disease. J. Virol. 2011, 85(21):11479-11489.
14. Castillo-Olivares J., Calvo-Pinilla E., Casanova I., Bachanek-Bankowska K., Chiam R., Maan S., Nieto J.M., Ortego J., Mertens P.P. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS ONE 2011, 6(1):e16503.
15. Channappanavar R., Singh K.P., Singh R., Umeshappa C.S., Ingale S.L., Pandey A.B. Enhanced proinflammatory cytokine activity during experimental bluetongue virus-1 infection in Indian native sheep. Vet. Immunol. Immunopathol. 2012, 145(1-2):485-492.
16. Chauveau E., Doceul V., Lara E., Adam M., Breard E., Sailleau C., Viarouge C., Desprat A., Meyer G., Schwartz-Cornil I., Ruscanu S., Charley B., Zientara S., Vitour D. Sensing and control of bluetongue virus infection in epithelial cells via RIG-I and MDA5 helicases. J. Virol. 2012, 86(21):11789-11799.
17. Chen M.F., Lin Y., Xia Y.C., Sun C., Feng X.M., Lu M.J., Yang D.L., Wu J. Establishment and application of hepatitis B virus persistent replication model in IFNAR(-/-) mouse. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013, 33(3):392-397.
18. de la Poza F., Calvo-Pinilla E., Lopez-Gil E., Marin-Lopez A., Mateos F., Castillo-Olivares J., Lorenzo G., Ortego J. Ns1 is a key protein in the vaccine composition to protect ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus. PLoS ONE 2013, 8(7):e70197.
19. Delebecque F., Combredet C., Gabet A.S., Wattel E., Brahic M., Tangy F. A chimeric human T cell leukemia virus type I bearing a deltaR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses. J. Infect. Dis. 2005, 191(2):255-263.
20. DeMaula C.D., Leutenegger C.M., Bonneau K.R., MacLachlan N.J. The role of endothelial cell-derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue. Virology 2002, 296(2):330-337.
21. Drew C.P., Heller M.C., Mayo C., Watson J.L., MacLachlan N.J. Bluetongue virus infection activates bovine monocyte-derived macrophages and pulmonary artery endothelial cells. Vet. Immunol. Immunopathol. 2010, 136(3-4):292-296.
22. Eschbaumer M., Keller M., Beer M., Hoffmann B. Epizootic hemorrhagic disease virus infection of type I interferon receptor deficient mice. Vet. Microbiol. 2012, 155(2-4):417-419.
23. Fiette L., Aubert C., Muller U., Huang S., Aguet M., Brahic M., Bureau J.F. Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J. Exp. Med. 1995, 181(6):2069-2076.
24. Foster N.M., Luedke A.J., Parsonson I.M., Walton T.E. Temporal relationships of viremia, interferon activity, and antibody responses of sheep infected with several bluetongue virus strains. Am. J. Vet. Res. 1991, 52(2):192-196.
25. Franceschi V., Capocefalo A., Calvo-Pinilla E., Redaelli M., Mucignat-Caretta C., Mertens P., Ortego J., Donofrio G. Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 2011, 29(16):3074-3082.
26. Franchi P., Mercante M.T., Ronchi G.F., Armillotta G., Ulisse S., Molini U., Di Ventura M., Lelli R., Savini G., Pini A. Laboratory tests for evaluating the level of attenuation of bluetongue virus. J. Virol. Methods 2008, 153(2):263-265.
27. Fulton R.W., Pearson N.J. Interferon induction in bovine and feline monolayer cultures by four bluetongue virus serotypes. Can. J. Comp. Med. 1982, 46(1):100-102.
28. Gumm I.D., Newman J.F. The preparation of purified bluetongue virus group antigen for use as a diagnostic reagent. Arch. Virol. 1982, 72(1-2):83-93.
29. Hemati B., Contreras V., Urien C., Bonneau M., Takamatsu H.H., Mertens P.P., Breard E., Sailleau C., Zientara S., Schwartz-Cornil I. Bluetongue virus targets conventional dendritic cells in skin lymph. J. Virol. 2009, 83(17):8789-8799.
30. Huismans H. Bluetongue virus-induced interferon synthesis. Onderstepoort J. Vet. Res. 1969, 36(2):181-185.
31. Ida-Hosonuma M., Iwasaki T., Yoshikawa T., Nagata N., Sato Y., Sata T., Yoneyama M., Fujita T., Taya C., Yonekawa H., Koike S. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 2005, 79(7):4460-4469.
32. Jabbar T.K., Calvo-Pinilla E., Mateos F., Gubbins S., Bin-Tarif A., Bachanek-Bankowska K., Alpar O., Ortego J., Takamatsu H.H., Mertens P.P., Castillo-Olivares J. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS ONE 2013, 8(4):e60574.
33. Jameson P., Grossberg S.E. Production of interferon in human cell cultures by a new, potent viral inducer. Adv. Exp. Med. Biol. 1978, 110:37-53.
34. Jameson P., Grossberg S.E. Induction of interferon with bluetongue virus in various cells. Methods Enzymol. 1981, 78(Pt A):254-258.
35. Jameson P., Schoenherr C.K., Grossberg S.E. Bluetongue virus, an exceptionally potent interferon inducer in mice. Infect. Immun. 1978, 20(1):321-323.
36. Jauniaux T.P., De Clercq K.E., Cassart D.E., Kennedy S., Vandenbussche F.E., Vandemeulebroucke E.L., Vanbinst T.M., Verheyden B.I., Goris N.E., Coignoul F.L. Bluetongue in Eurasian lynx. Emerg. Infect. Dis. 2008, 14(9):1496-1498.
37. Jeggo M.H., Wardley R.C., Brownlie J. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology 1984, 52(3):403-410.
38. Jeggo M.H., Wardley R.C., Taylor W.P. Role of neutralising antibody in passive immunity to bluetongue infection. Res. Vet. Sci. 1984, 36(1):81-86.
39. Johansson C., Wetzel J.D., He J., Mikacenic C., Dermody T.S., Kelsall B.L. Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus. J. Exp. Med. 2007, 204(6):1349-1358.
40. Lopez-Gil E., Lorenzo G., Hevia E., Borrego B., Eiden M., Groschup M., Gilbert S.C., Brun A. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl. Trop. Dis. 2013, 7(7):e2309.
41. Lorenzo G., Martin-Folgar R., Hevia E., Boshra H., Brun A. Protection against lethal Rift valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 2010, 28(17):2937-2944.
42. Ma G., Eschbaumer M., Said A., Hoffmann B., Beer M., Osterrieder N. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS ONE 2012, 7(4):e34425.
43. MacLachlan N.J., Crafford J.E., Vernau W., Gardner I.A., Goddard A., Guthrie A.J., Venter E.H. Experimental reproduction of severe bluetongue in sheep. Vet. Pathol. 2008, 45(3):310-315.
44. MacLachlan N.J., Drew C.P., Darpel K.E., Worwa G. The pathology and pathogenesis of bluetongue. J. Comp. Pathol. 2009, 141(1):1-16.
45. MacLachlan N.J., Jagels G., Rossitto P.V., Moore P.F., Heidner H.W. The pathogenesis of experimental bluetongue virus infection of calves. Vet. Pathol. 1990, 27(4):223-229.
46. MacLachlan N.J., Thompson J. Bluetongue virus-induced interferon in cattle. Am. J. Vet. Res. 1985, 46(6):1238-1241.
47. Mellor P.S., Hamblin C. African horse sickness. Vet. Res. 2004, 35(4):445-466.
48. Mrkic B., Pavlovic J., Rulicke T., Volpe P., Buchholz C.J., Hourcade D., Atkinson J.P., Aguzzi A., Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 1998, 72(9):7420-7427.
49. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264(5167):1918-1921.
50. Narayan O., Johnson R.T. Effects of viral infection on nervous system development. I. Pathogenesis of bluetongue virus infection in mice. Am. J. Pathol. 1972, 68(1):1-14.
51. Ohka S., Igarashi H., Nagata N., Sakai M., Koike S., Nochi T., Kiyono H., Nomoto A. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J. Virol. 2007, 81(15):7902-7912.
52. Operschall E., Schuh T., Heinzerling L., Pavlovic J., Moelling K. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. J. Clin. Virol. 1999, 13(1-2):17-27.
53. Pavlovic J., Schultz J., Hefti H.P., Schuh T., Molling K. DNA vaccination against La Crosse virus. Intervirology 2000, 43(4-6):312-321.
54. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89(Pt 1):1-47.
55. Richards W.P., Cordy D.R. Bluetongue virus infection: pathologic responses of nervous systems in sheep and mice. Science 1967, 156(3774):530-531.
56. Rojas J.M., Rodriguez-Calvo T., Pena L., Sevilla N. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine 2011, 29(40):6848-6857.
57. Ruscanu S., Pascale F., Bourge M., Hemati B., Elhmouzi-Younes J., Urien C., Bonneau M., Takamatsu H., Hope J., Mertens P., Meyer G., Stewart M., Roy P., Meurs E.F., Dabo S., Zientara S., Breard E., Sailleau C., Chauveau E., Vitour D., Charley B., Schwartz-Cornil I. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway. J. Virol. 2012, 86(10):5817-5828.
58. Saegerman C., Berkvens D., Mellor P.S. Bluetongue epidemiology in the European union. Emerg. Infect. Dis. 2008, 14(4):539-544.
59. Sanchez-Cordon P.J., Pedrera M., Risalde M.A., Molina V., Rodriguez-Sanchez B., Nunez A., Sanchez-Vizcaino J.M., Gomez-Villamandos J.C. Potential role of proinflammatory cytokines in the pathogenetic mechanisms of vascular lesions in goats naturally infected with bluetongue virus serotype 1. Transbound. Emerg. Dis. 2013, 60(3):252-262.
60. Sanchez-Cordon P.J., Pleguezuelos F.J., Perez de Diego A.C., Gomez-Villamandos J.C., Sanchez-Vizcaino J.M., Ceron J.J., Tecles F., Garfia B., Pedrera M. Comparative study of clinical courses, gross lesions, acute phase response and coagulation disorders in sheep inoculated with bluetongue virus serotype 1 and 8. Vet. Microbiol. 2013, 166(1-2):184-194.
61. Schwartz-Cornil I., Mertens P.P., Contreras V., Hemati B., Pascale F., Breard E., Mellor P.S., MacLachlan N.J., Zientara S. Bluetongue virus: virology, pathogenesis and immunity. Vet. Res. 2008, 39(5):46.
62. Tudor D., Riffault S., Carrat C., Lefevre F., Bernoin M., Charley B. Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C. Virology 2001, 286(1):197-205.
63. Umeshappa C.S., Singh K.P., Ahmed K.A., Pandey A.B., Nanjundappa R.H. The measurement of three cytokine transcripts in naive and sensitized ovine peripheral blood mononuclear cells following in vitro stimulation with bluetongue virus serotype-23. Res. Vet. Sci. 2011, 90(2):212-214.
64. Umeshappa C.S., Singh K.P., Pandey A.B., Singh R.P., Nanjundappa R.H. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep. Vaccine 2010, 28(13):2522-2531.
65. Vancott J.L., McNeal M.M., Choi A.H., Ward R.L. The role of interferons in rotavirus infections and protection. J. Interferon Cytokine Res. 2003, 23(3):163-170.
66. Verwoerd D.A.B.E. Bluetongue. Infectious Diseases of Livestock 2004, Oxford University Press, Oxford, UK. 2nd ed. J.A.W. Coetzer (Ed.).
67. Volker I., Bach P., Coulibaly C., Plesker R., Abel T., Seifried J., Heidmeier S., Muhlebach M.D., Lauer U.M., Buchholz C.J. Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques. Hum. Gene Ther. Clin. Dev. 2013, 24(1):11-22.
68. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., Fleming M.J., Mertens P.P., Black D.N. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996, 220(1):227-231.
69. Wernike K., Breithaupt A., Keller M., Hoffmann B., Beer M., Eschbaumer M. Schmallenberg virus infection of adult type I interferon receptor knock-out mice. PLoS ONE 2012, 7(7):e40380.
70. Winkelmann E.R., Widman D.G., Xia J., Ishikawa T., Miller-Kittrell M., Nelson M.H., Bourne N., Scholle F., Mason P.W., Milligan G.N. Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling. Vaccine 2012, 30(8):1465-1475.
71. Worwa G., Hilbe M., Chaignat V., Hofmann M.A., Griot C., Ehrensperger F., Doherr M.G., Thur B. Virological and pathological findings in Bluetongue virus serotype 8 infected sheep. Vet. Microbiol. 2010, 144(3-4):264-273.
72. Zivcec M., Safronetz D., Scott D., Robertson S., Ebihara H., Feldmann H. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 2013, 207(12):1909-1921.